Last updated: September 2, 2026
Technetium Tc-99m exametazime kit, marketed historically as Ceretec, is a mature nuclear-medicine diagnostic product used primarily for labeling leukocytes and imaging cerebral blood flow. Its core composition, technetium Tc-99m exametazime, is long off patent in practical commercial terms. Current value is driven by manufacturing reliability, radiopharmacy distribution, hospital utilization, and the availability of competing imaging agents rather than by exclusivity.
Product-specific revenue is not publicly disclosed by GE HealthCare or other commercial suppliers. The product is best characterized as a niche, mature diagnostic franchise with limited pricing power, low patent-based entry barriers, and operational exposure to isotope supply and short shelf life.
What is technetium Tc-99m exametazime used for?
Technetium Tc-99m exametazime is a radiopharmaceutical kit that is reconstituted and labeled with technetium-99m before administration. The principal clinical applications are:
| Application |
Clinical purpose |
Commercial relevance |
| Leukocyte labeling |
Localization of suspected infection or inflammation |
Core hospital and radiopharmacy use |
| Cerebral perfusion imaging |
Assessment of regional cerebral blood flow |
Smaller and more specialized indication |
| Nuclear medicine imaging |
Single-photon emission computed tomography |
Dependent on local nuclear-medicine infrastructure |
For leukocyte imaging, exametazime is used ex vivo to label a patient’s white blood cells. The labeled cells are then reinjected and imaged. The process requires trained staff, sterile handling, validated radiopharmacy procedures, and rapid coordination because technetium-99m has a physical half-life of approximately six hours.
The FDA-approved product is a kit for the preparation of technetium Tc-99m exametazime injection. It is not a therapeutic drug and does not create biosimilar competition because it is a small-molecule diagnostic radiopharmaceutical rather than a biologic.[1]
When does technetium Tc-99m exametazime lose exclusivity?
Technetium Tc-99m exametazime has no meaningful remaining U.S. regulatory exclusivity. The product received FDA approval in the early 1990s, and any original new chemical entity, orphan, or pediatric exclusivity periods have expired.[1]
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
No current exclusivity identified |
| Pediatric exclusivity |
No current exclusivity identified |
| Regulatory exclusivity |
None expected to remain from the original approval |
| Patent-based exclusivity |
No commercially meaningful term expected to remain for the original active ingredient |
The practical implication is that a competitor does not need to wait for an upcoming loss-of-exclusivity date. Market access depends on FDA approval, manufacturing capability, radiopharmaceutical distribution, and customer contracts.
What patents protect technetium Tc-99m exametazime?
The original chemical and imaging-related patent estate is mature. Any foundational patents covering exametazime chemistry or its use in technetium labeling would have been filed decades ago and are expected to be expired in the United States and other major markets.
No current Orange Book patent position is expected to create a material barrier to generic or alternative kit entry. The FDA Orange Book generally lists patents and exclusivity associated with approved drug products, but it does not provide a complete record of every possible process, formulation, device, trade-secret, or foreign patent right.[2]
Are formulation patents still important?
Formulation patents are unlikely to provide substantial current protection for the original kit. The commercial product is a radiopharmaceutical preparation kit rather than a complex sustained-release dosage form. Potentially protectable elements may include:
- Stabilizer composition
- Vial configuration
- Lyophilization process
- Reconstitution conditions
- Radiolabeling yield
- Storage and handling procedures
- Quality-control specifications
These features can create regulatory and manufacturing know-how advantages even when they do not support enforceable patent exclusivity. The principal competitive barrier is process execution rather than a blocking patent.
Are method-of-use patents relevant?
Method-of-use patent risk is limited. The principal uses, including labeled leukocyte imaging and cerebral perfusion imaging, are longstanding clinical applications. New claims involving a specific imaging protocol, patient-selection method, or combined diagnostic workflow could be pursued, but they would not ordinarily restore broad exclusivity for the kit.
What is the FDA and Orange Book status of technetium Tc-99m exametazime?
The product is an FDA-approved diagnostic radiopharmaceutical kit. The original U.S. product is associated with the Ceretec name and has historically been linked to GE HealthCare and its predecessor organizations.[1]
| Regulatory issue |
Assessment |
| FDA status |
Approved diagnostic radiopharmaceutical kit |
| Dosage form |
Kit for preparation of technetium Tc-99m injection |
| Therapeutic category |
Nuclear medicine diagnostic agent |
| Biologic status |
Not a biologic |
| Biosimilar pathway |
Not applicable |
| Orange Book relevance |
Relevant for listed patents and approval data, but no active exclusivity is expected |
| Regulatory pathway for competitors |
Abbreviated or conventional drug approval may be possible depending on product and reference-drug status |
| REMS |
No major REMS burden associated with the product |
| Controlled substance status |
Not a controlled substance |
A competitor could face FDA review of chemistry, manufacturing and controls, sterility, radiochemical purity, labeling, stability, and clinical performance. Radiopharmaceutical applications also face operational review because the product must be prepared and used within a narrow time window.
How many patents cover technetium Tc-99m exametazime?
No active patent count can be used as a reliable measure of commercial protection for the product. The relevant distinction is between:
- Foundational patents on exametazime chemistry, which are expected to have expired.
- Historical patents on labeling methods or imaging uses, which are also mature.
- Later process or formulation patents, which may have limited scope or geographic coverage.
- Unpublished manufacturing know-how, which cannot be assessed through the Orange Book.
The active patent estate should therefore be considered weak from a market-exclusion perspective. A company could still obtain narrow patents on a new kit configuration or manufacturing process, but those rights would not necessarily prevent competition with the established product.
Which companies are challenging or competing with Ceretec?
Competition comes from both substitute radiopharmaceuticals and alternative diagnostic technologies.
Radiopharmaceutical competitors
| Competitor or substitute |
Active component or technology |
Main overlap |
| Technetium Tc-99m HMPAO |
Tc-99m exametazime-related leukocyte-labeling and perfusion applications |
Direct or near-direct substitution |
| Indium In-111 oxine |
In-111-labeled leukocytes |
Infection and inflammation imaging |
| Technetium Tc-99m bicisate |
Tc-99m ECD |
Cerebral perfusion imaging |
| FDG-PET |
Fluorodeoxyglucose |
Infection, inflammation, and oncology workflows |
| MRI and CT |
Non-radioactive imaging modalities |
Anatomic and inflammatory imaging |
Technetium Tc-99m HMPAO is the most relevant direct comparison because exametazime is the active ligand used in the HMPAO labeling technology. In practice, hospitals may compare products based on labeling efficiency, image quality, procedure time, local availability, reimbursement, and radiopharmacy support.
Manufacturer and distribution competition
The market may include originator-linked supply, radiopharmacy providers, and regional nuclear-medicine distributors. The identity of the commercial supplier can vary by country and over time because nuclear-medicine products are often distributed through local radiopharmacy networks rather than conventional retail-pharmacy channels.
The critical competitive asset is reliable supply at the time of the scheduled procedure. A supplier with a lower list price may still lose business if it cannot provide consistent kit availability or technical support.
How does the product’s supply chain affect market dynamics?
Technetium Tc-99m exametazime has a more complex supply chain than conventional injectable drugs.
Isotope dependence
Technetium-99m is generated from molybdenum-99/technetium-99m systems. Supply interruptions can result from reactor outages, molybdenum production constraints, generator shortages, transportation problems, and radiopharmacy capacity limits. The drug manufacturer may not control the full isotope chain.
Short shelf life
The six-hour physical half-life of technetium-99m creates a time-sensitive commercial model:
- Kits must reach radiopharmacies before scheduled procedures.
- Radiolabeling must occur close to administration.
- Delivery failures can result in cancelled or rescheduled scans.
- Inventory cannot be managed like conventional pharmaceutical stock.
- Local or regional manufacturing often has greater value than centralized distribution.
Manufacturing barriers
The main barriers include:
- Sterile lyophilized-kit production
- Radiochemical quality control
- Validated leukocyte-labeling procedures
- Compatibility with generator-produced technetium
- Stability testing
- Specialized regulatory documentation
- Nuclear-medicine customer support
These barriers are meaningful operationally but do not create durable monopoly protection. An experienced radiopharmaceutical manufacturer could potentially enter if it has the required facility, quality system, regulatory resources, and distribution network.
What is the financial trajectory for technetium Tc-99m exametazime?
The product’s financial trajectory is mature rather than growth-oriented. Product-specific sales are not separately reported in public filings, so revenue, gross margin, and market share cannot be assigned with precision.
Commercial life-cycle assessment
| Period |
Financial and market characteristics |
| 1990s |
Launch and adoption in nuclear medicine |
| 2000s |
Expansion of routine hospital and radiopharmacy use |
| 2010s |
Mature demand, increasing substitution and pricing pressure |
| 2020-2021 |
Procedure disruption from reduced hospital activity and pandemic restrictions |
| 2022 onward |
Recovery tied to nuclear-medicine procedure volumes, isotope supply, and customer retention |
The economic profile is likely shaped by recurring but relatively low-volume hospital demand. Revenue is generated from kit sales, while the ultimate procedure also depends on technetium supply, radiopharmacy preparation, and hospital staffing.
Revenue drivers
The main positive drivers are:
- Growth in nuclear-medicine imaging capacity
- Stable infection and inflammation imaging demand
- Expansion of radiopharmacy networks
- Improved availability of medical isotopes
- Continued use of leukocyte scintigraphy where PET or MRI is unavailable
- Long-term hospital contracts and standardized protocols
Revenue constraints
The main constraints are:
- Low or absent patent pricing power
- Substitution by FDG-PET, MRI, CT, and other agents
- Complex ex vivo leukocyte-labeling workflow
- Short product and isotope timelines
- Limited number of nuclear-medicine sites
- Procedure reimbursement pressure
- Periodic isotope shortages
- Lack of separately reported product economics
The product should not be valued as a growth pharmaceutical asset. Its value is closer to that of a specialized, supply-constrained diagnostic product with recurring institutional demand.
What generic entry risks exist for technetium Tc-99m exametazime?
Generic entry risk is structurally high because the original product is mature and has no evident current market exclusivity. The risk is tempered by the difficulty of demonstrating reliable kit performance and building a radiopharmacy distribution footprint.
| Risk factor |
Impact on incumbent |
| Expired foundational IP |
High |
| No meaningful remaining exclusivity |
High |
| Complex sterile manufacturing |
Moderate barrier |
| Radiochemical validation |
Moderate barrier |
| Short shelf life |
Moderate barrier |
| Limited market size |
Reduces attractiveness to entrants |
| Hospital switching costs |
Moderate retention benefit |
| Isotope supply constraints |
Can affect all suppliers |
| Product-specific clinical familiarity |
Supports incumbent retention |
A new entrant would not need to displace the entire installed base. It could target selected radiopharmacies, hospital systems, or regions where supply reliability and price are more important than brand continuity.
Which companies are challenging the product through settlement or litigation?
No major, widely reported Paragraph IV litigation or settlement involving technetium Tc-99m exametazime is evident from the product’s mature regulatory history and lack of current Orange Book exclusivity.
Paragraph IV litigation is less likely than in high-value oral medicines because:
- The underlying product is old.
- Annual market value is likely modest relative to blockbuster drugs.
- The patent estate does not appear to contain a current broad blocking right.
- Commercial entry requires specialized isotope and radiopharmacy infrastructure.
- A competitor may pursue a conventional approval or alternative product strategy rather than litigate.
Any future dispute would more likely concern a narrow process patent, trade secret, distribution agreement, regulatory filing, product shortage, or quality issue than a broad composition-of-matter patent.
How does technetium Tc-99m exametazime compare with In-111 leukocyte imaging?
| Factor |
Tc-99m exametazime |
In-111 oxine |
| Isotope half-life |
Approximately six hours |
Approximately 67 hours |
| Imaging timing |
Same day is feasible |
Often delayed imaging |
| Radiation characteristics |
Generally favorable for gamma imaging |
Higher-energy emissions and longer retention |
| Workflow |
Rapid but operationally demanding |
More flexible timing after labeling |
| Supply chain |
Highly dependent on Tc-99m generators |
Dependent on In-111 supply |
| Clinical use |
Common leukocyte and perfusion applications |
Leukocyte imaging, including delayed imaging |
| Commercial disadvantage |
Short timing window |
Longer procedure cycle and isotope cost considerations |
Tc-99m exametazime is commercially attractive when same-day imaging and standard nuclear-medicine infrastructure are available. In-111 may retain value where delayed imaging, longer tracking, or local protocol preferences justify the alternative.
What is the geographic coverage of the patent and commercial estate?
The original patent estate is expected to be expired or commercially weak in major markets, including the United States and Europe. Commercial availability remains more geographically variable than patent coverage.
Supply depends on:
- Local regulatory approval
- National radiopharmaceutical distribution rules
- Availability of Tc-99m generators
- Hospital nuclear-medicine capacity
- Import and transportation controls
- Regional radiopharmacy networks
A product may have little patent protection but still face limited competition in a particular country because only one supplier has an approved kit or dependable distribution system.
How strong is the patent estate for technetium Tc-99m exametazime?
The patent estate is weak as a source of exclusivity and moderate as a source of historical know-how. The original active ingredient and principal clinical applications are mature. Any residual value lies in narrow process claims, manufacturing expertise, quality systems, regulatory history, and customer relationships.
| Asset category |
Strength |
| Composition-of-matter protection |
Very weak or expired |
| Method-of-use protection |
Weak |
| Formulation protection |
Limited and potentially narrow |
| Manufacturing know-how |
Moderate |
| Regulatory dossier |
Moderate |
| Distribution infrastructure |
Moderate to strong in constrained regions |
| Brand recognition |
Moderate among nuclear-medicine users |
| Switching barrier |
Moderate for established hospital protocols |
Key Takeaways
- Technetium Tc-99m exametazime kit is a mature diagnostic radiopharmaceutical, historically marketed as Ceretec.
- The FDA-approved product is used mainly for labeled leukocyte imaging and cerebral perfusion imaging.
- Original drug exclusivity and foundational patent protection have expired.
- No current Orange Book position is expected to provide meaningful market exclusivity.
- Biosimilar risk is not applicable because the product is a small-molecule diagnostic kit.
- Generic entry is legally easier than operational entry because sterile manufacturing, radiochemical testing, isotope access, and radiopharmacy distribution are difficult.
- Product-specific revenue and profitability are not publicly disclosed.
- Financial performance is likely stable but modest, with exposure to procedure volume, isotope supply, and substitution by PET, MRI, CT, and other radiopharmaceuticals.
- The strongest commercial defenses are supply reliability, regulatory history, hospital familiarity, and regional distribution.
- Paragraph IV litigation and settlement risk appear limited relative to branded products with active patents.
FAQs
Is technetium Tc-99m exametazime the same as Ceretec?
Yes. Ceretec is the historical brand associated with technetium Tc-99m exametazime kit. Commercial branding and supplier arrangements can vary by market.
Is technetium Tc-99m exametazime a generic drug?
The active chemical technology is mature, but regulatory classification depends on the specific applicant and product. A competing kit would still require FDA approval demonstrating appropriate quality, labeling, manufacturing controls, and product performance.
Does technetium Tc-99m exametazime have biosimilar competition?
No. Biosimilar approval applies to biological products. Technetium Tc-99m exametazime is a small-molecule radiopharmaceutical diagnostic product.
What is the biggest commercial risk for the product?
The largest risks are supply disruption, low procedure growth, substitution by PET or other imaging methods, and competitive kit entry after the expiration of foundational intellectual property.
Can a hospital substitute another leukocyte-labeling agent?
Potential substitution depends on the clinical indication, institutional protocol, physician preference, isotope availability, regulatory status, and reimbursement. In-111 oxine and other imaging methods can compete with Tc-99m exametazime in selected workflows.
References
- U.S. Food and Drug Administration. (n.d.). Ceretec: Technetium Tc 99m exametazime kit prescribing information. Drugs@FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
- Society of Nuclear Medicine and Molecular Imaging. (n.d.). Appropriate use and procedural guidance for radiolabeled leukocyte imaging. SNMMI.
- Organisation for Economic Co-operation and Development. (2019). The supply of medical radioisotopes: An economic diagnosis and possible solutions. OECD Nuclear Energy Agency.
- GE HealthCare. (2024). Annual report and Form 10-K. GE HealthCare Technologies Inc.
